Canakinumab in the treatment of tumour necrosis factor receptor-associated periodic syndrome (TRAPS) - European Medical Journal

Canakinumab in the treatment of tumour necrosis factor receptor-associated periodic syndrome (TRAPS)

Oncology

At the American College of Rheumatology Annual Meeting, which took place in San Francisco, California, USA, from 6 to 11 November 2015, Helen Lachmann, MA, MB BChir, MD, FRCP, from the Royal Free London NHS Foundation Trust, London, UK discusses the results of a trial which analysed the use of canakinumab to treat tumour necrosis factor receptor-associated periodic syndrome (TRAPS), and how they relate to her own experiences in the UK.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now